<PAGE>


Exhibit 99.7


         MIV THERAPEUTICS WELCOMES DR. ARUN CHOCKALINGAM SPECIAL ADVISOR
                       SCIENTIFIC & INTERNATIONAL AFFAIRS


VANCOUVER, Nov. 4 /PRNewswire-FirstCall/ -- MIV Therapeutics Inc. (MIVT:OTCBB &
MIV1:FSE) is pleased to announce that Dr. Arun Chockalingam, BE, MS, PhD, FACC,
FACEP has accepted our invitation to act as Special Advisor on Scientific &
International Affairs.

Dr. Chockalingam is a Clinical Professor of Health Care and Epidemiology at the
University of British Columbia in Vancouver, British Columbia. He holds degrees
in Electronics Engineering, Biomedical Engineering and Medicine. He is an
accomplished author, educator, lecturer and internationally recognized
cardiovascular expert. Canada's two major television networks interviewed him
regarding the "GLOBAL BURDEN OF HEART DISEASE" in July 2001. Dr. Chockalingam
received the Dr. Harold N. Segall Award of Merit by The Canadian Cardiovascular
Society for outstanding contribution to the progress of cardiovascular disease
prevention in Canada. He received a Letter of Recognition from the Minister of
Health, Alan Rock, for developing and producing the "Healthy Heart Kit", a
Health Canada policy manual, aimed at professional and patient education and
endorsed by the Canadian Medical Association. In recognition of his global
contribution to cardiovascular health, the American College of Cardiology
presented him with an honorary fellowship, (FACC) in March 2000.

Dr. Chockalingam has over 20 years of academia and governmental (senior policy
adviser at Health Canada) experience and continues as a consultant to the World
Health Organization, the Pan American Health Organization, the World Heart
Federation, and a number of national cardiovascular organizations in many
countries. In 1999, on behalf of the World Heart Federation he edited and
published the book entitled "IMPENDING GLOBAL PANDEMIC OF CARDIOVASCULAR DISEASE
(CVD): CHALLENGES AND OPPORTUNITIES FOR PREVENTION AND CONTROL OF CVD IN
DEVELOPING COUNTRIES AND ECONOMIES IN TRANSITION", which is now used by many
countries as a policy document. He has authored or co-authored over 100
scientific/medical publications. Dr. Chockalingam has chaired and/or organized a
number of national and international conferences on hypertension control,
preventive cardiology, stroke prevention, and Heart Health and is Co-Chair of
the Conference Organizing Committee for The 5th International Heart Health
Conference to be held June 13-16, 2004 in Milan, Italy.

Alan Lindsay, President and CEO of MIVT, comments, "Dr. Chockalingam has
collaborated on and conducted over 70 Phase III & IV cardiovascular clinical
trials and has a passion for the growing global burden of cardiovascular
disease. His understanding of the socio-medical needs of developing countries
and his professional connections around the world are an invaluable resource for
MIVT. We are honored that he has accepted this critical role at this important
time in MIVT's growth curve".

Dr. Chockalingam adds, "MIVT's hydroxyapatite (HAp) biocompatible stent coatings
would be an attractive alternative to the polymer based coatings currently being
used to treat cardiovascular disease. MIVT's HAp nano-film passive coating
should offer developing nations with limited access to cardiovascular
interventions, a cost efficient treatment solution. The multi- layer coating is
progressing through an R&D program and has shown promising results with respect
to nano-porosity and drug encapsulation for drug-eluting stents (DES). I look
forward to working closely with the MIVT team to make their unique technologies
universally available".

TECHNOLOGICAL MILESTONES

MIVT recently announced significant milestones. The first was the success of an
independent animal trial of its unique hydroxyapatite (HAp) stent coating. The
trial, "THROMBOGENICITY ASSAY IN DOGS", conducted to evaluate any evidence of
clotting in the blood stream, was performed by Toxikon Corporation in Bedford,
Massachusetts under the direction of Dr. Chin Tay (PhD.) The trial was compliant
with U.S. FDA 21 CFR, part 58 and Good Laboratory Practices regulations.
Stainless steel and cobalt-chromium stents coated with MIVT's biocompatible HAp
coating were both used in the study.


<PAGE>

Dr. Tay, Toxikon's Director of Toxicology, stated, "The animal trial performed
at Toxikon evaluated the thrombogenicity of MIV Therapeutics' HAp coated stents
in the blood stream. MIVT's HAp coated stents performed well, with minimal to no
significant thrombosis, thus successfully meeting the scientific and regulatory
requirements."

On Sept 24, MIVT announced the achievement of a critical milestone of its
government assisted multi-layer drug-eluting coating program, "Functionally
Gradient Calcium Phosphate Coatings for Stents". These included reproducibility
of the coating, coating integrity and suitability for drug encapsulation for
drug elution purposes.


ABOUT MIV THERAPEUTICS

MIV Therapeutics is developing a "NEXT GENERATION" line of advanced
biocompatible stent coatings and therapeutics for stent-based drug-delivery
systems. The Company has completed development of a line of proprietary coronary
stents for use in angioplasty procedures and is in late-stage development of its
HAp (hydroxyapatite) stent coating technology, licensed from the University of
British Columbia. In addition, MIVT's manufacturing facility maintains a
comprehensive QA (Quality Assurance) system which meets the guidelines of ISO
9001 (1994) and ISO 13485 (1996) requirements, complies with applicable FDA
guidelines and applicable GMP requirements and is capable of private label
manufacturing and out sourcing.